A lipoprotein lipase–GPI-anchored high-density lipoprotein–binding protein 1 fusion lowers triglycerides in mice: Implications for managing familial chylomicronemia syndrome
Copyright policy )A lipoprotein lipase–GPI-anchored high-density lipoprotein–binding protein 1 fusion lowers triglycerides in mice: Implications for managing familial chylomicronemia syndrome
Lipoprotein lipase (LPL) is central to triglyceride metabolism. Severely compromised LPL activity causes familial chylomicronemia syndrome (FCS), which is associated with very high plasma triglyceride levels and increased risk of life-threatening pancreatitis. Currently, no approved pharmacological intervention can acutely lower plasma triglycerides in FCS. Low yield, high aggregation, and poor stability of recombinant LPL have thus far prevented development of enzyme replacement therapy. Recently, we showed that LPL monomers form 1:1 complexes with the LPL transporter glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) and solved the structure of the complex. In the present work, we further characterized the monomeric LPL/GPIHBP1 complex and its derivative, the LPL-GPIHBP1 fusion protein, with the goal of contributing to the development of an LPL enzyme replacement therapy. Fusion of LPL to GPIHBP1 increased yields of recombinant LPL, prevented LPL aggregation, stabilized LPL against spontaneous inactivation, and made it resistant to inactivation by the LPL antagonists angiopoietin-like protein 3 (ANGPTL3) or ANGPTL4. The high stability of the fusion protein enabled us to identify LPL amino acids that interact with ANGPTL4. Additionally, the LPL-GPIHBP1 fusion protein exhibited high enzyme activity in in vitro assays. Importantly, both intravenous and subcutaneous administrations of the fusion protein lowered triglycerides in several mouse strains without causing adverse effects. These results indicate that the LPL-GPIHBP1 fusion protein has potential for use as a therapeutic for managing FCS.
- Novartis Institutes for BioMedical Research Switzerland
- Novartis (Switzerland) Switzerland
Male, Binding Sites, Protein Stability, Recombinant Fusion Proteins, Infusions, Subcutaneous, Mice, Inbred C57BL, Disease Models, Animal, Lipoprotein Lipase, Mice, Protein Aggregates, Angiopoietin-like Proteins, Mice, Inbred DBA, Angiopoietin-Like Protein 4, Animals, Humans, Editors' Picks, Enzyme Replacement Therapy, Hyperlipoproteinemia Type I, Amino Acid Sequence, Angiopoietin-Like Protein 3, Receptors, Lipoprotein
Male, Binding Sites, Protein Stability, Recombinant Fusion Proteins, Infusions, Subcutaneous, Mice, Inbred C57BL, Disease Models, Animal, Lipoprotein Lipase, Mice, Protein Aggregates, Angiopoietin-like Proteins, Mice, Inbred DBA, Angiopoietin-Like Protein 4, Animals, Humans, Editors' Picks, Enzyme Replacement Therapy, Hyperlipoproteinemia Type I, Amino Acid Sequence, Angiopoietin-Like Protein 3, Receptors, Lipoprotein
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).18 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!